| Autor: |
Chun, D. S., Yin, Y., Anderson‐Smits, C. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p787-788, 2p |
| Abstrakt: |
In this ad-hoc analysis, the primary objectives were to evaluate HGG incidence and IVIG use in patients with DLBCL who received CAR-T therapy. B Introduction: b Chimeric antigen receptor T-cell (CAR-T) therapy is a treatment for patients with diffuse large B-cell lymphoma (DLBCL) and is associated with toxicities, including hypogammaglobulinemia (HGG). B Aim: b To describe the real-world incidence of HGG and the effectiveness of IVIG after CAR-T therapy in patients with DLBCL. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text